The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.